Morgan Stanley analyst Terence Flynn raised the firm’s price target on AbbVie (ABBV) to $241 from $239 and keeps an Overweight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Trump Plans “Major Tariff on Pharmaceuticals” as Global Economies Crumble
- AbbVie Hold Rating: Balancing Strong Immunology Growth with Challenges in Aesthetics, Neuroscience, and Oncology
- AbbVie reports European Commission grants marketing authorization to Rinvoq
- AbbVie assumed with a Neutral at Goldman Sachs
- Salesforce, Block, AbbVie, Applied Materials, Oracle: Insider Moves Unveiled!